These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23973432)

  • 1. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
    Hammer LA; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Sep; 98():122-31. PubMed ID: 23973432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis.
    Hammer LA; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2015 Mar; 112():42-51. PubMed ID: 25647234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
    Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
    Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
    McLaughlin PJ; McHugh DP; Magister MJ; Zagon IS
    BMC Immunol; 2015 Apr; 16():24. PubMed ID: 25906771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
    Rahn KA; McLaughlin PJ; Zagon IS
    Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum [Met
    Ludwig MD; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2017 Sep; 134():1-9. PubMed ID: 28647454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.
    Zhang GX; Yu S; Gran B; Li J; Calida D; Ventura E; Chen X; Rostami A
    J Neuroimmunol; 2004 Mar; 148(1-2):1-10. PubMed ID: 14975581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The magnitude of the antigen-specific T cell response is separated from the severity of spinal cord histopathology in remitting-relapsing experimental autoimmune encephalomyelitis.
    Batoulis H; Uhl M; Addicks K; Lehmann PV; Kuerten S
    Glia; 2012 May; 60(5):794-805. PubMed ID: 22319015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
    Whitham RH; Bourdette DN; Hashim GA; Herndon RM; Ilg RC; Vandenbark AA; Offner H
    J Immunol; 1991 Jan; 146(1):101-7. PubMed ID: 1701788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread.
    Takács K; Chandler P; Altmann DM
    Eur J Immunol; 1997 Nov; 27(11):2927-34. PubMed ID: 9394820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
    Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
    J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Effects on Central Nervous System by Acidic Polysaccharide of Panax ginseng in Relapse-Remitting Experimental Autoimmune Encephalomyelitis-Induced SJL/J Mice.
    Bing SJ; Ha D; Hwang I; Park E; Ahn G; Song JY; Jee Y
    Am J Chin Med; 2016; 44(6):1099-1110. PubMed ID: 27627913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
    Patel C; Zagon IS; Pearce-Clawson M; McLaughlin PJ
    J Neurosci Res; 2022 Feb; 100(2):551-563. PubMed ID: 34821408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.